Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis

Wei Fan Hsu, Chi Yi Chen, Kuo Chih Tseng, Hsueh Chou Lai, Hsing Tao Kuo, Chao Hung Hung, Shui Yi Tung, Jing Houng Wang, Jyh Jou Chen, Pei Lun Lee, Rong Nan Chien, Chun Yen Lin, Chi Chieh Yang, Gin Ho Lo, Chi Ming Tai, Chih Wen Lin, Jia Horng Kao, Chun Jen Liu, Chen Hua Liu, Sheng Lei YanMing Jong Bair, Wei Wen Su, Cheng Hsin Chu, Chih Jen Chen, Ching Chu Lo, Pin Nan Cheng, Yen Cheng Chiu, Chia Chi Wang, Jin Shiung Cheng, Wei Lun Tsai, Han Chieh Lin, Yi Hsiang Huang, Pei Chien Tsai, Jee Fu Huang, Chia Yen Dai, Wan Long Chuang, Ming Lung Yu, Cheng Yuan Peng

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m2 was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients.

Original languageEnglish
Article number5372
JournalScientific reports
Volume10
Issue number1
DOIs
Publication statusPublished - 2020 Dec 1

All Science Journal Classification (ASJC) codes

  • General

Fingerprint Dive into the research topics of 'Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this